{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:47:22Z","timestamp":1769100442104,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejogrb.2021.06.006","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:57:05Z","timestamp":1623459425000},"page":"79-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Early-onset preeclampsia \u2013 The impact of antiphospholipid antibodies on disease severity"],"prefix":"10.1016","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7746-3594","authenticated-orcid":false,"given":"Roni","family":"Zemet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai","family":"Dulitzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadas","family":"Ofer Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Morag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal J.","family":"Simchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejogrb.2021.06.006_b0005","first-page":"e1","article-title":"Gestational hypertension and preeclampsia","volume":"133","author":"ACOG Practice Bulletin No. 202","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.semperi.2011.09.011","article-title":"Maternal mortality from preeclampsia\/eclampsia","volume":"36","author":"Ghulmiyyah","year":"2012","journal-title":"Semin Perinatol"},{"issue":"6","key":"10.1016\/j.ejogrb.2021.06.006_b0020","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jash.2008.10.001","article-title":"Hypertension in pregnancy","volume":"2","author":"Lindheimer","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0025","first-page":"467","article-title":"Preeclampsia: pathophysiology, diagnosis, and management","volume":"7","author":"Uzan","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0b013e3282f1a953","article-title":"Non-proteinuric preeclampsia: a novel risk indicator in women with gestational hypertension","volume":"26","author":"Homer","year":"2008","journal-title":"J Hypertens"},{"issue":"807\u201333","key":"10.1016\/j.ejogrb.2021.06.006_b0035","first-page":"vii","article-title":"Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome","volume":"31","author":"Barton","year":"2004","journal-title":"Clin Perinatol"},{"issue":"4","key":"10.1016\/j.ejogrb.2021.06.006_b0040","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/0002-9378(93)90043-I","article-title":"Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)","volume":"169","author":"Sibai","year":"1993","journal-title":"Am J Obstet Gynecol"},{"issue":"5 Pt 1","key":"10.1016\/j.ejogrb.2021.06.006_b0045","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/01.AOG.0000126245.35811.2a","article-title":"Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count","volume":"103","author":"Sibai","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.06.006_b0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.AOG.0000152351.13671.99","article-title":"Diagnosis, prevention, and management of eclampsia","volume":"105","author":"Sibai","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(10)61351-7","article-title":"Prediction of adverse maternal outcomes in preeclampsia: development and validation of the fullPIERS model. PIERS Study Group","volume":"377","author":"von Dadelszen","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejogrb.2021.06.006_b0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/OGX.0b013e3182331028","article-title":"A critical review of early-onset and late-onset preeclampia","volume":"66","author":"Raymond","year":"2011","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0065","first-page":"4108271","article-title":"Early- and late-onset preeclampsia: a comprehensive cohort study of laboratory and clinical findings according to the new ISHHP criteria","author":"W\u00f3jtowicz","year":"2019","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0070","article-title":"Clinical risk factors for preeclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. High Risk of Preeclampsia Identification Group","volume":"353","author":"Bartsch","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0075","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/HYPERTENSIONAHA.107.107565","article-title":"Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study","volume":"51","author":"Chappell","year":"2008","journal-title":"Hypertension"},{"issue":"7491","key":"10.1016\/j.ejogrb.2021.06.006_b0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/bmj.38380.674340.E0","article-title":"Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies","volume":"330","author":"Duckitt","year":"2005","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejogrb.2021.06.006_b0085","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/01.AOG.0000423816.39542.0f","article-title":"Antiphospholipid syndrome","volume":"120","author":"ACOG Practice Bulletin No. 132","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0090","first-page":"614","article-title":"Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience","volume":"80","author":"Branch","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0095","first-page":"131","article-title":"A study of sixty pregnancies in patients with the antiphospholipid syndrome","volume":"14","author":"Lima","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jri.2008.11.001","article-title":"Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes","volume":"79","author":"Yamada","year":"2009","journal-title":"J Reprod Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.ejogrb.2021.06.006_b0105","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0049-3848(17)30064-6","article-title":"Antiphospholid antibodies and the risk of pregnancy complications","volume":"151","author":"Gris","year":"2017","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.ejogrb.2021.06.006_b0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.autrev.2018.12.006","article-title":"The european registry on obstetric antiphospholipid syndrome (EUROAPS): A survey of 1000 consecutive cases","volume":"18","author":"Alijotas-Reig","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.ejogrb.2021.06.006_b0115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/GCO.0000000000000406","article-title":"Current insights in obstetric antiphospholipid syndrome","volume":"29","author":"Schreiber","year":"2017","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0002-9378(90)90376-I","article-title":"The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing?","volume":"162","author":"Sibai","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ejogrb.2021.06.006_b0125","first-page":"311","article-title":"Birth weight standards in the live-born population in Israel","volume":"7","author":"Dollberg","year":"2005","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0130","doi-asserted-by":"crossref","unstructured":"Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000 Jul; 183(1): S1-S22.","DOI":"10.1067\/mob.2000.107928"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0135","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0140","first-page":"541","article-title":"The association of antiphospholipid antibodies with severe preeclampsia","volume":"73","author":"Branch","year":"1989","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9378(91)90222-D","article-title":"The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth retardation","volume":"165","author":"Milliez","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0150","first-page":"105","article-title":"The association of antiphospholipid antibodies with severe early-onset preeclampsia","volume":"85","author":"Moodley","year":"1995","journal-title":"S Afr Med J"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.ejogrb.2021.06.006_b0160","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1177\/0961203318787035","article-title":"Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study","volume":"27","author":"Gibbins","year":"2018","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.ejogrb.2021.06.006_b0165","doi-asserted-by":"crossref","first-page":"525.e1","DOI":"10.1016\/j.ajog.2017.01.026","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ejogrb.2021.06.006_b0170","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1177\/0961203319852155","article-title":"Obstetric outcomes in patients with primary thrombotic and obstetric antiphospholipid syndrome and its relation to the antiphospholipid antibody profile","volume":"28","author":"H\u00f6gd\u00e9n","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0175","doi-asserted-by":"crossref","unstructured":"do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: A systematic review and meta-analysis. Obstet Gynecol 2010; 116: 1433\u20131443","DOI":"10.1097\/AOG.0b013e3181fe02ec"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2011.02.006","article-title":"The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis","volume":"128","author":"Abou-Nassar","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0185","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/path.2893","article-title":"Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss","volume":"225","author":"Cohen","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0190","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0195","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0200","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1191\/0961203303lu397oa","article-title":"Activation of complement mediates antiphospholipid antibody-induced pregnancy loss","volume":"12","author":"Salmon","year":"2003","journal-title":"Lupus"},{"issue":"167","key":"10.1016\/j.ejogrb.2021.06.006_b0205","first-page":"e1","article-title":"Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies","volume":"196","author":"Shamonki","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2021.06.006_b0210","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/ard.2004.031856","article-title":"Real world experience with antiphospholipid antibody tests: how stable are results over time?","volume":"64","author":"Erkan","year":"2005","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211521002773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211521002773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:52:56Z","timestamp":1759557176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211521002773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":42,"alternative-id":["S0301211521002773"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2021.06.006","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early-onset preeclampsia \u2013 The impact of antiphospholipid antibodies on disease severity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2021.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}